iDX HPV 16/18/45 Screening Kit
Targeted Screening:
This kit specifically detects the three most aggressive high-risk HPV types—16, 18, and 45.
Oncogenic Importance: Types 16 and 18 are responsible for about 70% of cervical cancers globally, while Type 45 is the third most common type in invasive cervical cancer. Detecting these specific genotypes is critical for identifying patients at the highest risk.
2. Ultra-High Analytical Sensitivity:
Our iDX protocol is powered by a system Low Limit of Detection (LoD): It can detect as little as 48 IU/mL, ensuring even low viral-load infections are caught.
3. Human-Verified Quality Control:
We go beyond simple internal controls. iDX utilizes the Human RNase P gene as an internal verification for every sample. This confirms that enough human cellular material was collected and that the extraction was successful, providing 100% confidence in every negative result.
HPV Gene Coverage
Targeted detection of the 3 most critical high-risk HPV genotypes.
3 High Risk HPV genotypes detected
- HPV 16
- HPV 18
- HPV 45
Working Hours: Monday-Saturday, 9:00 AM - 7:00 PM
Clinical Diagnostic Process
Targeted molecular screening provides precise detection of the 3 most oncogenic HPV strains.
Why Choose iDX HPV 16/18/45 Screening Kit
- Targets the 3 most aggressive high-risk HPV types
- Types 16 & 18 cause 70% of cervical cancers
- Ultra-Low LoD of 48 IU/mL catches low viral loads
- Human RNase P gene verification for 100% confidence
Your questions, answered clearly
Types 16, 18, and 45 are responsible for the vast majority of HPV-related cervical cancers, making this a focused, high-impact screen.
It can detect as little as 48 IU/mL, catching even low viral-load infections.
Yes, the Human RNase P gene is used as an internal verification to ensure extraction success.